| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8598152 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US10238668 | KOWA PHARMS | Co-crystals of tramadol and coxibis |
Apr, 2030
(5 years from now) | |
| US9012440 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US10245276 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10548909 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US11478488 | KOWA PHARMS | Co-crystals of tramadol and coxibs |
Apr, 2030
(5 years from now) | |
| US8846744 | KOWA PHARMS | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
Jun, 2031
(7 years from now) | |
Seglentis is owned by Kowa Pharms.
Seglentis contains Celecoxib; Tramadol Hydrochloride.
Seglentis has a total of 7 drug patents out of which 0 drug patents have expired.
Seglentis was authorised for market use on 15 October, 2021.
Seglentis is available in tablet;oral dosage forms.
Seglentis can be used as a method for treatment of pain in adults using tramadol hydrochloride and celecoxib.
The generics of Seglentis are possible to be released after 03 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for treatment of pain in adults using tramadol hydrochloride and celecoxib
Dosage: TABLET;ORAL
SEGLENTIS family patents
